Search

Author/Creator Gavriatopoulou, M.

2. P1105: FINAL RESULTS OF THE PHASE I/II HOVON124/ECWM-R2 STUDY INCLUDING 2-YEAR RITUXIMAB MAINTENANCE AFTER INDUCTION WITH IXAZOMIB, RITUXIMAB AND DEXAMETHASONE IN RELAPSED WALDENSTRÖM'S MACROGLOBULINEMIA. (23rd June 2022)

Authors:
Dimopoulos, M.-A.; Amaador, K.; Minnema, M. C.; Nasserinejad, K.; Kap, M.; Kastritis, E.; Gavriatopoulou, M.; Kraan, W.; Chamuleau, M. E. D.; Deeren, D.; Tick, L.; Doorduijn, J. K.; Offner, F.; Böhmer, L. H.; Liu, R. D.; Pals, S. T.; Vos, J. M.; Kersten, M. J.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
995
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. P916: COEXISTENCE OF ≥2 HIGH-RISK MOLECULAR ABNORMALITIES SUPERVENES THE PROGNOSTIC VALUE OF THE REVISED INTERNATIONAL STAGING SYSTEM FOR MYELOMA: REAL-WORLD DATA ANALYSIS FROM THE GREEK MYELOMA STUDY GROUP. (23rd June 2022)

Authors:
Katodritou, E.; Dalampira, D.; Triantafyllou, T.; Gavriatopoulou, M.; Delimpasi, S.; Pouli, A.; Papadopoulou, T.; Verrou, E.; Sevastoudi, A.; Tsirou, K.; Katsika, L.; Douganiotis, G.; Karampatzakis, N.; Metallinou, T.-E.; Palaska, V.; Kotsopoulou, M.; Lalayianni, C.; Kyrtsonis, M.-C.; Spanoudakis...
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
806
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. P926: DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: RESULTS FROM THE PHASE 2 GMMG-DANTE TRIAL. (23rd June 2022)

Authors:
Leypoldt, L.; Gavriatopoulou, M.; Besemer, B.; Salwender, H.; Raab, M.-S.; Nogai, A.; Khandanpour, C.; Runde, V.; Zago, M.; Martus, P.; Goldschmidt, H.; Bokemeyer, C.; Dimopoulos, M.; Weisel, K.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
816
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. S178: SAFETY AND EFFICACY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH RD IN NEWLY DIAGNOSED, TRANSPLANT INELIGIBLE MULTIPLE MYELOMA PATIENTS: A PHASE 1/2 STUDY BY THE HELLENIC SOCIETY OF HEMATOLOGY. (23rd June 2022)

Authors:
Terpos, E.; Gavriatopoulou, M.; Ntanasis-Stathopoulos, I.; Malandrakis, P.; Fotiou, D.; Kanellias, N.; Gkolfinopoulos, S.; Manousou, K.; Kastritis, E.; Dimopoulos, M.-A.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
79
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search